Filing Flows

Filing Flows › Health Care › Angiodynamics (ANGO)

Angiodynamics (ANGO) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Oct 8, 2026 · Angiodynamics (ANGO) Q1 FY27 earnings results →

Q1 FY27 Revenue up 7% year over year to $80.9M · 9¢ of every $1 of revenue lost · operating margin -9.0%

Angiodynamics made $80.9M in Q1 FY27 (+7% Y/Y): Med Device $41.0M, Med Tech $39.9M. Operating margin -9.0%, net loss $7.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 8, 2026.

Revenue$80.9M
Year over year+7%
Operating margin-9.0%
Net earnings−$7.1M
Operating cash flow−$15.3M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $80.9M in Q1 FY27, up 7% year over year and down 7% from the previous quarter. Med Device was the largest line at 51% of revenue. Med Tech added $4.7M year over year (up 13%), 89% of the total change.

Gross margin was 59.4%, up 4.1 points from Q1 FY26. Operating costs exceeded revenue by $7.3M, an operating margin of -9.0%. Operating expenses grew 5% against revenue growth of 7%. The fastest-growing cost line was Research & development (+24%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $11.4M loss.

Operating cash flow was −$15.3M. Non-cash charges added back $5.5M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $18.2M. Capital expenditures of $379K exceeded it, leaving free cash flow of −$15.7M.

Quarterly history

Angiodynamics revenue by quarterAngiodynamics revenue by quarter$72.0MQ3 FY25$80.2MQ4 FY25$75.7MQ1 FY26$79.4MQ2 FY26$78.4MQ3 FY26$86.6MQ4 FY26$80.9MQ1 FY27
Angiodynamics net earnings by quarterAngiodynamics net earnings by quarter−$4.4MQ3 FY25−$6.0MQ4 FY25−$10.9MQ1 FY26−$6.3MQ2 FY26−$8.1MQ3 FY26−$11.4MQ4 FY26−$7.1MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QOct 8, 2026$80.9M+7%-9.0%−$7.1M−$15.3M
Q4 FY2610-KJul 14, 2026$86.6M+8%-11.8%−$11.4M$17.5M
Q3 FY2610-QApr 2, 2026$78.4M+9%-16.5%−$8.1M−$3.1M
Q2 FY2610-QJan 6, 2026$79.4M+9%-7.7%−$6.3M$4.7M
Q1 FY2610-QOct 2, 2025$75.7M+12%-14.1%−$10.9M−$15.9M
Q4 FY2510-KJul 18, 2025$80.2M+13%-7.2%−$6.0M$18.8M
Q3 FY2510-QApr 2, 2025$72.0M-4%-13.9%−$4.4M−$13.2M

Charts

Angiodynamics: revenue growth, year over year and quarter over quarterAngiodynamics: revenue growth, year over year and quarter over quarterY/YQ/Q-4%Q3 FY25+13%+11%Q4 FY25+12%-6%Q1 FY26+9%+5%Q2 FY26+9%-1%Q3 FY26+8%+10%Q4 FY26+7%-7%Q1 FY27
Latest (Q1 FY27): Y/Y +7%, Q/Q -7%.
Angiodynamics: where the cash came from (+) and went (−), TTM to Q1 FY27Angiodynamics: where the cash came from (+) and went (−), TTM to Q1 FY27Other investing−$5.3MCash drawn (+) / kept (−)$4.8MOperating cash flow$3.7MCapital spending−$2.2MOther financing−$571KNet borrowing (+) / repaid (−)−$383KExchange rates$38K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Angiodynamics: profit against cash, quarter by quarterAngiodynamics: profit against cash, quarter by quarterNet incomeOperating cash flow−$10.7M$2.5MQ2 FY25−$4.4M−$13.2MQ3 FY25−$6.0M$18.8MQ4 FY25−$10.9M−$15.9MQ1 FY26−$6.3M$4.7MQ2 FY26−$8.1M−$3.1MQ3 FY26−$11.4M$17.5MQ4 FY26−$7.1M−$15.3MQ1 FY27
Latest (Q1 FY27): Net income −$7.1M, Operating cash flow −$15.3M.
Angiodynamics: diluted shares by fiscal yearAngiodynamics: diluted shares by fiscal year38MFY2139MFY2239MFY2340MFY2441MFY2542MFY26
+8.3% since FY21: more shares outstanding (issuance, stock pay).
Angiodynamics in its industry: growth against margin (111 companies, SIC 3841)Angiodynamics in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSANGO (+7%, -9%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Angiodynamics

AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility.

In its own words, from its 10-K, filed Jul 14, 2026.

Angiodynamics against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +7% against the peers' median +5%. Operating margin: -9.0% against the peers' median 13.3%.

CompanyQuarterRevenueY/YOp. margin
ANGO AngiodynamicsQ1 FY27$80.9M+7%-9.0%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Angiodynamics 10-Q on SEC EDGAR · CIK 1275187 · Surgical & Medical Instruments & Apparatus

13F: who owns ANGO and who is buying

Largest holders of ANGO (13F)Largest holders of ANGO (13F)BlackRock$49.5MPoint72 Asset Management, L.P.$39.8MSystematic Financial Management LP$34.3MVanguard Group$31.3MArmistice Capital, LLC$28.6MRoyce & Associates LP$25.6MBroadfin Holdings LLC$23.7MVanguard Capital Management LLC$22.0MKotler Kevin$22.0MWeber Capital Management LLC$20.8M
Funds' net buying of ANGO by quarter (13F)Funds' net buying of ANGO by quarter (13F)−$6.5M2024-09−$10.4M2024-12$28.4M2025-03$21.0M2025-06$16.6M2025-09−$39.9M2025-12−$4.8M2026-03−$7.2M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ANGO

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare ANGO with

中文版：Angiodynamics（ANGO）财报

Español · Français